Carboplatin + etoposide + atezolizumab (or durvalumab)
Checked 2026-09-09
Extensive-stage SCLC, first line
One cycle
every 21 days × 4 · about 12 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Carboplatin Cytotoxic chemotherapy (platinum) | AUC 5 | IV | D1 | |
Etoposide Topoisomerase II inhibitor (podophyllotoxin derivative) | 100 mg/m² | IV | D1-3 | |
Atezolizumab 1,200 mg (IMpower133) or durvalumab 1,500 mg (CASPIAN) Monoclonal antibody (anti-PD-L1) | day 1; maintenance every 3-4 weeks | IV | D1 |
Cycles
4, then checkpoint inhibitor maintenance until progression
21-day cycle
Emetogenicity
Moderate (30-90%)
G-CSF
Not routine
Notes
- IMforte: lurbinectedin added to atezolizumab maintenance improves PFS and OS.
Used in
Trials
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Cisplatin + etoposide (EP)
Limited-stage SCLC with concurrent thoracic radiotherapy; stage III NSCLC chemoradiation; high-grade neuroendocrine carcinoma
every 21 days × 4
Topotecan
Relapsed SCLC; platinum-resistant ovarian or cervical cancer
every 21 days
Tarlatamab
Extensive-stage SCLC after platinum-based chemotherapy
every 14 days